Anton, S. F. & Revicki, D. A. (1995) The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone. Psychopharmacology Bulletin, 31, 249–258.
Australian Government (1995) Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee Including Major Submissions Involving Economic Analysis. Canberra: Australian Government Publishing Service.
Azimi, N. A. & Welch, G. H. (1998) The effectiveness of cost-effectiveness analysis in containing costs. Journal of General Internal Medicine, 13, 664–669.
Bentkover, J. D. & Feighner, J. P. (1996) Cost analysis of paroxetine vs imipramine in major depression. Pharmacoeconomics, 8, 223–232.
Borghi, J. & Guest, J. F. (2000) Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. European Psychiatry, 15, 378–387.
Boyer, P., Danion, J. M., Bisserbe, J. C., et al (1998) Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. Pharmacoeconomics, 13, 157–169.
Brown, M. C., Nimmerrichter, A. A. & Guest, J. F. (1999a) Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria. European Psychiatry: Journal of the Association of European Psychiatrists, 14, 230–244.
Brown, M. C., van Loon, J. M. T. & Guest, J. F. (1999b) Cost-effectiveness of mirtazapine relative to amitriptyline in the treatment of moderate and severe depression in France. European Journal of Psychiatry, 13, 197–208.
Canadian Coordinating Office for Health Technology Assessment (1994) Guidelines for Economic Evaluation of Pharmaceuticals. Ottawa: CCOHTA.
Canadian Coordinating Office for Health Technology Assessment (1998) Selective serotonin reuptake inhibitors (SSRIs) for major depression. Part II: The cost effectiveness of SSRIs in treatment of depression. August 1997. Report 4E. Evidence-Based Medicine, 3, 87.
Casciano, J., Doyle, J., Arikian, S., et al (2001) The health economic impact of antidepressant usage from a payer's perspective: a multinational study. International Journal of Clinical Practice, 55, 292–299.
Cook, J. R. (1999) Challenges in economic outcomes research. Hepatology, 29, 23S–25S.
Croghan, T. W., Lair, T. J., Engelhart, L., et al (1997) Effect of antidepressant therapy on health care utilization and costs in primary care. Psychiatric Services, 48, 1420–1426.
Croghan, T. W., Kniesner, T. J., Melfi, C. A., et al (2000) Effect of antidepressant choice on the incidence and economic intensity of hospitalization among depressed individuals. Administration and Policy in Mental Health, 27, 183–195.
Crown, W. H., Hylan, T. R. & Meneades, L. (1998) Antidepressant selection and use and healthcare expenditures – an empirical approach. Pharmacoeconomics, 13, 435–448.
Davidson, R. A. (1986) Source of funding and outcome of clinical trials. Journal of General Internal Medicine, 1, 155–158.
Detsky, A. S. (1994) Using cost-effectiveness analysis for formulary decision making: from theory into practice. Pharmacoeconomics, 6, 281–288.
Djulbegovic, B., Lacevic, M., Cantor, A., et al (2000) The uncertainty principle and industry-sponsored research. Lancet, 356, 635–638.
Doyle, J. J., Casciano, J., Arikian, S., et al (2001) A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD); a comparison of cost-effectiveness between venlafaxine, SSRIs, and TCAs. Value in Health, 4, 16–31.
Drummond, M. F. (1998) A reappraisal of economic evaluation of pharmaceuticals: science or marketing?
Pharmacoeconomics, 14, 1–9.
Einarson, T. R., Arikian, S., Sweeney, S., et al (1995) A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clinical Therapeutics, 17, 136–153.
Einarson, T. R., Addis, A. & Iskedjian, M. (1997) Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. Pharmacoeconomics, 12, 286–296.
Forder, J., Kavanagh, S. & Fenyo, A. (1996) A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. Journal of Affective Disorders, 38, 97–111.
Freemantle, N. & Mason, J. (1997) Publication bias in clinical trials and economic analyses
Pharmacoeconomics, 12, 10–16.
Friedberg, M., Saffran, B., Stinson, T. J., et al (1999) Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA, 282, 1453–1475.
Gagnon, J. P. (2000) Sources of bias in the economic analysis of new drugs (letter). JAMA, 283, 1423.
Griffiths, R. I., Sullivan, E. M., Frank, R. G., et al (1999) Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Pharmacoeconomics, 15, 495–505.
Gulati, S. C. & Bitran, J. D. (1995) Cost-effectiveness analysis: sleeping with an enemy or a friend?
Journal of Clinical Oncology, 13, 2152–2154.
Hatziandreu, E. J., Brown, R. E., Revicki, D. A., et al (1994) Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics, 5, 249–264.
Hill, S. R., Mitchell, A. S. & Henry, D. A. (2000) Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA, 283, 2116–2121.
Hillman, A. L., Eisenberg, J. M., Pauly, M. V., et al (1991) Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies
New England Journal of Medicine, 324, 1362–1365
Hillman, B. J., Joseph, C. A., Magel, M. R., et al (1990) Frequency and costs of diagnostic imaging in office practice: a comparison of self referring and radiologist referring physicians
New England Journal of Medicine, 323, 1504–1508
Hotopf, M., Lewis, G. & Normand, C. (1996) Are SSRIs a cost-effective alternative to tricyclics?
British Journal of Psychiatry, 168, 404–409
Hylan, T. R., Kotsanos, J. G., Andersen, J. S., et al (1996) Comparison of a decision analytic model with results from a naturalistic economic clinical trial: an application of evaluating alternative antidepressants
American Journal of Managed Care, 2, 1211–1223
Hylan, T. R., Crown, W. H., Meneades, L., et al (1998) Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis
Journal of Affective Disorders, 47, 71–79
Jones, M. T. & Cockrum, P. C. (2000) A critical review of published economic modelling studies in depression. Pharmacoeconomics, 17, 555–583.
Jonsson, B. & Bebbington, P. (1993) Economic studies of the treatment of depressive illness. In Health Economics of Depression (eds Jonsson, B. & Rosenbaum, J.), pp. 35–48. Chichester: John Wiley.
Jonsson, B. & Bebbington, P. (1994) What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. British Journal of Psychiatry, 164, 665–673.
Lapierre, Y., Bentkover, J., Schainbaum, S., et al (1995) Direct costs of depression: analysis of treatment costs of paroxetine versus imipramine in Canada. Canadian Journal of Psychiatry, 40, 370–377.
Laupacis, A., Feeny, D., Detsky, A. S., et al (1992) How attractive does a new technology have to be to warrant adoption and utilization?
Canadian Medical Association Journal, 146, 473–481.
Le Pen, C., Levy, E., Ravily, V., et al (1994) The cost of treatment dropout in depression: a cost-benefit analysis of fluoxetine vs. tricyclics. Journal of Affective Disorders, 31, 1–18.
Luce, B. R. (1995) Policy implications of modelling the cost-effectiveness of health care technologies. Drug Information Journal, 29, 1469–1475.
Mandelkern, M. (1999) Manufacturer support and outcome (letter). Journal of Clinical Psychiatry, 60, 122.
Maynard, A. & Cookson, R. F. (1998) Computer modelling: the need for careful evaluation and public audit. Pharmacoeconomics, 14, 67–72.
McCabe, C. & Dixon, S. (2000) Testing the validity of cost-effectiveness models. Pharmacoeconomics, 17, 501–513.
McFarland, B. H. (1994) Cost-effectiveness considerations for managed care systems: treating depression in primary care. American Journal of Medicine, 97(suppl. 6A), 47S–58S.
Melton, S. T., Kirkwood, C. K., Farrar, T. W., et al (1997) Economic evaluation of paroxetine and imipramine in depressed outpatients. Psychopharmacology Bulletin, 33, 93–100.
Montgomery, S. A., Brown, R. E. & Clark, M. (1996) Economic analysis of treating depression with nefazodone v. imipramine. British Journal of Psychiatry, 168, 768–771.
Neumann, P. J. (1998) Paying the piper for pharmacoeconomic studies. Medical Decision Making, 18, S23–26.
Neumann, P. J., Sandberg, E. A., Bell, C., et al (2000a) Are pharmaceuticalls cost-effective? A review of the evidence. Health Affairs, 19, 92–109.
Neumann, P. J., Stone, P. W., Chapman, R. H., et al (2000b) The quality of reporting in published cost–utility analyses, 1976–1997. Annals of Internal Medicine, 132, 964–972.
Nuijten, M. J. C., Hardens, M. & Soutre, E. (1995) A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression. Pharmacoeconomics, 8, 159–168.
Nurnberg, G. H., Hensley, P. L., Thompson, P. M., et al (1999) Modeling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors. Psychiatric Services, 50, 1351–1353.
Obenchain, R. L., Melfi, C. A., Croghan, T. W., et al (1997) Bootstrap analyses of cost effectiveness in antidepressant pharmacotherapy. Pharmacoeconomics, 11, 464–472.
O'Brien, B. (1996) Economic evaluation of pharmaceuticals: Frankenstein's monster or vampire of trials?
Medical Care, 34, DS99–108.
Ontario Ministry of Health (1994) Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Toronto: Ontario Ministry of Health, Drug Programs Branch.
Poret, A. W., Neslusan, C., Ricci, J., et al (2001) Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants. Value in Heallth, 4, 362–369.
Rennie, D. & Flanagin, A. (1992) Publication bias: the triumph of hope over experience. JAMA, 267, 411–412.
Rennie, D. & Luft, H. S. (2000) Pharmacoeconomic analyses: making them transparent, making them credible. JAMA, 283, 2158–2160.
Revicki, D. A., Brown, R. E., Palmer, W., et al (1995) Modelling the cost effectiveness of antidepressant treatment in primary care. Pharmacoeconomics, 8, 524–540.
Revicki, D. A., Brown, R. E., Keller, M. B., et al (1997) Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. Journal of Clinical Psychiatry, 58, 47–58.
Rochon, P. A., Gurwitz, J. H., Simms, R. W., et al (1994) A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Archives of Internal Medicine, 154, 157–163.
Russell, J. M., Berndt, E. R., Miceli, R., et al (1999) Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline. American Journal of Managed Care, 5, 597–606.
Sacristan, J. A., Bolanos, E., Soto, J., et al (1997) Publication bias in health economic studies (letter). Pharmacoeconomics, 11, 289–290.
Sclar, D. A., Robison, L. M., Skaer, T. L., et al (1994) Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clinical Therapeutics, 16, 715–730.
Sclar, D. A., Robison, L. M., Skaer, T. L., et al (1995) Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization. Journal of International Medical Research, 23, 395–412.
Sclar, D. A., Skaer, T. L., Robison, L. M., et al (1998) Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis. Journal of Clinical Psychiatry, 59, 13–17.
Sclar, D. A., Skaer, T. L., Robison, L. M., et al (1999) Economic appraisal of citalopram in the management of single-episode depression. Journal of Clinical Psychopharmacology, 19, 47S–54S.
Sheldon, T. A. (1996) Problems of using modelling in the economic evaluation of health care. Health Economics, 5, I–II.
Siegel, J. E., Weinstein, M. C., Russell, L. B., et al (1996) Recommendations for reporting cost-effectiveness analyses. JAMA, 276, 1339–1341.
Simon, G. E. & Fishman, P. (1998) Cost implications of initial antidepressant selection in primary care. Pharmacoeconomics, 13, 61–70.
Simon, G. E., Heilegenstein, J. H., Revicki, D. A., et al (1999) Long-term outcomes of initial antidepressant drug choice in a ‘real world’ randomized trial. Archives of Family Medicine, 8, 319–325.
Skaer, T. L., Sclar, D. A., Robison, L. M., et al (1995) Economic evaluation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Current Therapeutic Research, 56, 556–567.
Smith, W. & Sherrill, A. (1996) A pharmacoeconomic study of the management of major depression: patients in a TennCare HMO. Medical Interface, 9, 88–92.
Stelfox, H. T., Chua, G., O'Rourke, K., et al (1998) Conflict of interest in the debate over calcium-channel antagonists. New England Journal of Medicine, 338, 101–106.
Stewart, A. (1994) Anti-depressant pharmacotherapy: cost comparison of SSRIs and TCAs. British Journal of Medical Economics, 7, 67–79.
Sullivan, E. M., Griffiths, R. I., Frank, R. G., et al (2000) One-year costs of second-line therapies for depression. Journal of Clinical Psychiatry, 61, 290–298.
Thompson, D., Hylan, T. R., McMullen, W., et al (1998) Predictors of a medical-offset effect among patients receiving antidepressant therapy. American Journal of Psychiatry, 155, 824–827.
Udrarhelyi, I. S., Graham, A., Rai, A., et al (1992) Cost-effectiveness and cost-benefit analyses in the medical literature: are the methods being used correctly?
Annals of Internal Medicine, 116, 238–244.
Wan, G. J., Crown, W. H., Berndt, E. R., et al (2002) Treatment costs of venlafaxine and selective serotoninreuptake inhibitors for depression and anxiety. Managed Care Interface, 15, 24–30.
Woods, S. W. & Baker, C. B. (1997) Cost-effectiveness of newer antidepressants. Current Opinion in Psychiatry, 10, 95–101.
Woods, S. W. & Baker, C. B. (2002) Cost effectiveness of the newer generation of antidepressants. In Psychopharmacology: The Fifth Generation of Progress (eds Davis, K. L., Coyle, J., Charney, D. S., et al), pp. 1119–1138. New York: Raven Press.
Woods, S. W. & Rizzo, J. A. (1997) Cost-effectiveness of antidepressant treatment reassessed. British Journal of Psychiatry, 170, 257–263.
Yee, G. C. & Hillman, A. L. (1997) Applied pharmacoeconomics: when can publication be legitimately withheld?
Pharmacoeconomics, 12, 511–516.